Delving into the Latest Updates on Harbin Pharm Group Sanjing Mingshui Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Cardiovascular Diseases

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

ACE(Angiotensin-converting enzyme)	1
SERT(Serotonin transporter)	1

主要目的:比较餐后给药条件下，哈药集团三精明水药业有限公司提供的拉西地平片（4mg/片）与GLAXOSMITHKLINE,S.A持证的拉西地平片（4mg/片，商品名：Lacipil®）在健康成年人群中吸收程度和速度的差异，评价其生物等效性。次要目的:评价餐后给药条件下，哈药集团三精明水药业有限公司提供的拉西地平片（4mg/片）与GLAXOSMITHKLINE,S.A持证的拉西地平片（4mg/片，商品名：Lacipil®）的安全性。

[Translation]

Primary objective: To compare the differences in absorption extent and speed of Lacidipine Tablets (4 mg/tablet) provided by Harbin Pharmaceutical Group Sanjingmingshui Pharmaceutical Co., Ltd. and Lacidipine Tablets (4 mg/tablet, trade name: Lacipil®) licensed by GLAXOSMITHKLINE, S.A. in healthy adults under the condition of postprandial administration, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of Lacidipine Tablets (4 mg/tablet) provided by Harbin Pharmaceutical Group Sanjingmingshui Pharmaceutical Co., Ltd. and Lacidipine Tablets (4 mg/tablet, trade name: Lacipil®) licensed by GLAXOSMITHKLINE, S.A. under the condition of postprandial administration.

Start Date07 Oct 2023

Sponsor / Collaborator

Harbin Pharm Group Sanjing Mingshui Pharmaceutical Co., Ltd.

CTR20230126 / CompletedNot Applicable

拉西地平片在健康受试者中开放、随机、单剂量、三周期、三序列、部分重复交叉空腹状态下和开放、随机、单剂量、双周期、双交叉餐后状态下的生物等效性试验

[Translation] An open, randomized, single-dose, three-period, three-sequence, partially repeated crossover bioequivalence study of lacidipine tablets in healthy subjects under fasting state and open, randomized, single-dose, two-period, double crossover fed state

主要目的：比较空腹及餐后给药条件下，哈药集团三精明水药业有限公司提供的拉西地平片（4 mg/片）与GLAXOSMITHKLINE,S.A持证的拉西地平片（4 mg/片，商品名：Lacipil®）在健康成年人群中吸收程度和速度的差异，评价其生物等效性。次要目的：评价空腹及餐后给药条件下，哈药集团三精明水药业有限公司提供的拉西地平片（4 mg/片）与GLAXOSMITHKLINE,S.A持证的拉西地平片（4 mg/片，商品名：Lacipil®）的安全性。

[Translation]

Primary objective: To compare the differences in the extent and rate of absorption of Lacidipine Tablets (4 mg/tablet) provided by Harbin Pharmaceutical Group Sanjingmingshui Pharmaceutical Co., Ltd. and Lacidipine Tablets (4 mg/tablet, trade name: Lacipil®) licensed by GLAXOSMITHKLINE, S.A. in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of Lacidipine Tablets (4 mg/tablet) provided by Harbin Pharmaceutical Group Sanjingmingshui Pharmaceutical Co., Ltd. and Lacidipine Tablets (4 mg/tablet, trade name: Lacipil®) licensed by GLAXOSMITHKLINE, S.A. under fasting and postprandial administration conditions.

Start Date14 Feb 2023

Sponsor / Collaborator

Harbin Pharm Group Sanjing Mingshui Pharmaceutical Co., Ltd.

CTR20190834 / Completed

阿莫西林胶囊在中国健康受试者中的单次给药、随机、开放、两周期、双交叉的生物等效性实验

[Translation] A single-dose, randomized, open-label, two-period, double-crossover bioequivalence study of amoxicillin capsules in Chinese healthy volunteers

考察健康受试者空腹及餐后单次口服受试制剂阿莫西林胶囊的人体药代动力学特征，以已上市的阿莫西林胶囊（AMOXIL®）为标准参比制剂，进行两周期双交叉设计的人体生物等效性研究，并观察受试制剂阿莫西林胶囊和参比制剂AMOXIL®在健康受试者中的安全性。

[Translation]

The pharmacokinetic characteristics of the test amoxicillin capsules were investigated after single oral administration on an empty stomach or after meals in healthy subjects. A two-period double-crossover bioequivalence study was conducted using the marketed amoxicillin capsules (AMOXIL®) as the standard reference preparation. The safety of the test amoxicillin capsules and the reference preparation AMOXIL® in healthy subjects was observed.

Start Date24 Apr 2019

Sponsor / Collaborator

Harbin Pharm Group Sanjing Mingshui Pharmaceutical Co., Ltd.

100 Clinical Results associated with Harbin Pharm Group Sanjing Mingshui Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Harbin Pharm Group Sanjing Mingshui Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Harbin Pharm Group Sanjing Mingshui Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Harbin Pharm Group Sanjing Mingshui Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

2

Login to view more data